Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study
Table 2
The multiple cox regression analysis results for mortalities of HD patients ().
Death causes
CVD
All-cause
Variable
HR
95% CI
value
HR
95% CI
value
Time-dependent covariates
Incident PAD cases with cilostazol user (new)
Versus cilostazol nonuser
0.11
0.03
0.51
0.0045
0.21
0.08
0.52
0.0008
Versus non-PAD group
0.14
0.02
0.8
0.0271
0.13
0.04
0.45
0.0013
Prevalence of PAD cases with cilostazol user (new)
Versus cilostazol nonuser
0.11
0.03
0.51
0.0045
0.21
0.08
0.52
0.0008
Versus non-PAD group
0.19
0.04
0.93
0.0397
0.33
0.12
0.87
0.0258
Prevalence of PAD cases with cilostazol user (existing)
Versus cilostazol user (new)
6.16
1.23
30.96
0.0272
1.89
0.62
5.8
0.2665
Versus cilostazol nonuser
0.7
0.25
1.93
0.4851
0.38
0.15
0.98
0.0451
Versus non-PAD group
1.19
0.41
3.51
0.7475
0.61
0.23
1.64
0.3321
Covariates at baseline
DM, yes versus no
2.67
1.19
6
0.0172
2.53
1.39
4.62
0.0024
CAD or CeVD present, yes versus no
8.78
3.43
22.49
<0.0001
4.7
2.49
8.87
<0.0001
DBP, ≤68 or >86 versus others (mmHg)
2.59
1.27
5.32
0.0092
3.19
1.82
5.59
<0.0001
SBP, ≤120 versus others (mmHg)
—
—
—
—
2.91
1.62
5.23
0.0003
BMI, >22.83 versus others (Kg/m2)
0.37
0.19
0.75
0.0056
0.32
0.19
0.55
<0.0001
Albumin, ≥3.5 versus others (g/dL)
0.09
0.02
0.32
0.0003
0.18
0.07
0.5
0.0009
HD vintage, 10~20 versus ≤10 (years)
—
—
—
—
0.14
0.03
0.61
0.009
Note: see the footnotes of Table 1 for abbreviations and definitions of longitudinal PAD status patterns. The dichotomous cut-off points for BMI were the median and the first quartile; those for DBP and hsCRP were the first and third quartiles. The asterisks “” indicate that statistically significant associations between outcomes and explanatory variables were observed at a 0.05 significance level.
